Medincell: Uzedy sales jump 96% in the third quarter, Teva raises its guidance
Net sales of Uzedy, a schizophrenia treatment based on Medincell's technology and marketed in the United States by Teva, reached $85 million in the third quarter of 2026. They are up 96% year on year, compared with +43% in the previous quarter. Following this, Teva raised its annual guidance to $290-310 million, from $270-290 million previously.
These figures are Teva's, not Medincell's revenue. However, they determine the royalties received by the Montpellier-based company and the milestone payments it may be entitled to. The same economic model will apply to Weltruza, the second product based on its technology, whose US launch is underway.
A 96% growth in the third quarter, after 43% in the second
Net sales of Uzedy in the United States rose each quarter of 2026: $63 million in the first quarter, $77 million in the second, and then $85 million in the third.
The year-on-year growth rate, however, varied: it was +62% in the first quarter and +43% in the second, before rising back to +96% in the most recent reported period.
Over the first nine months of the year, cumulative sales reached $225 million. This amount exceeds the $191 million recorded for the full year 2025, while the fourth quarter is still to come.
Prescriptions up 62% and a broader base of prescribers
According to Teva data reported by Medincell, Uzedy remains the long-acting injectable treatment for schizophrenia showing the strongest growth in the United States. The number of prescriptions, normalized in treatment months, rose 62% year on year.
Two drivers are cited: better access to the treatment in hospital settings and the continuous expansion of the prescriber base, which adds more than 800 new prescribers each month. The product, a subcutaneous formulation of risperidone, has been approved for schizophrenia since April 2023 and for bipolar I disorder since October 2025.
A forecast raised for the second time this year, Weltruza launching
The new range of $290-310 million represents the second upward revision this year. Teva had projected $250-280 million when it published its first-quarter results, then $270-290 million when it published its second-quarter results.
For Medincell, these sales translate into royalties at a rate between the middle and the upper end of a single-digit range. The company is also eligible for $105 million in commercial milestone payments, paid only if certain annual sales thresholds are reached.
The commercial portfolio is expanding with Weltruza, a monthly subcutaneous injection of olanzapine approved by the FDA in October 2026, whose US launch is underway. Both products fall under the same global license agreement with Teva, on the same economic terms.
In Europe, a marketing authorization application for long-acting olanzapine was accepted by the EMA in May 2026.
On November 2, 2026, Medincell's shares were up 16% over one month, driven by the US approval granted to this second formulation. Uzedy sales, on which the company's royalties are based, have thus already exceeded their 2025 level at the time a second product based on the same technology reaches the market.
